It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bi-allelic loss-of-function (LoF) variants in the base excision repair (BER) gene NTHL1 cause a high-risk hereditary multi-tumor syndrome that includes breast cancer, but the contribution of heterozygous variants to hereditary breast cancer is unknown. An analysis of 4985 women with breast cancer, enriched for familial features, and 4786 cancer-free women revealed significant enrichment for NTHL1 LoF variants. Immunohistochemistry confirmed reduced NTHL1 expression in tumors from heterozygous carriers but the NTHL1 bi-allelic loss characteristic mutational signature (SBS 30) was not present. The analysis was extended to 27,421 breast cancer cases and 19,759 controls from 10 international studies revealing 138 cases and 93 controls with a heterozygous LoF variant (OR 1.06, 95% CI: 0.82–1.39) and 316 cases and 179 controls with a missense variant (OR 1.31, 95% CI: 1.09–1.57). Missense variants selected for deleterious features by a number of in silico bioinformatic prediction tools or located within the endonuclease III functional domain showed a stronger association with breast cancer. Somatic sequencing of breast cancers from carriers indicated that the risk associated with NTHL1 appears to operate through haploinsufficiency, consistent with other described low-penetrance breast cancer genes. Data from this very large international multicenter study suggests that heterozygous pathogenic germline coding variants in NTHL1 may be associated with low- to moderate- increased risk of breast cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 Peter MacCallum Cancer Centre, Cancer Genetics Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville Familial Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
2 Peter MacCallum Cancer Centre, Cancer Genetics Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); Peter MacCallum Cancer Centre, Bioinformatics Core Facility, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
3 Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville Familial Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
4 Lifepool, Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
5 Peter MacCallum Cancer Centre, Upper Gastrointestinal Translational Research Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); The University of Melbourne, Department of Medicine, Royal Melbourne Hospital, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
6 Peter MacCallum Cancer Centre, Bioinformatics Core Facility, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
7 Peter MacCallum Cancer Centre, Cancer Genetics Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
8 Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
9 Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO); Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654); Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Area of Clinical and Molecular Genetics, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
10 Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); University of Melbourne, Melbourne, Department of Clinical Pathology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
11 The University of Melbourne, Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
12 Centre Hospitalier Universitaire de Québec – Université Laval Research Center, Genomics Center, Quebec, Canada (GRID:grid.411081.d) (ISNI:0000 0000 9471 1794)
13 University of Munich, Campus Großhadern, Department of Gynecology and Obstetrics, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
14 University of Cologne, Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); University of Cologne, Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
15 The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a); The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Division of Psychosocial Research and Epidemiology, Amsterdam, The Netherlands (GRID:grid.430814.a)
16 Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands (GRID:grid.430814.a)
17 Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada (GRID:grid.250674.2) (ISNI:0000 0004 0626 6184); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
18 University of Cologne, Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
19 University of Leipzig, Leipzig Research Centre for Civilization Diseases, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786); University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany (GRID:grid.9647.c) (ISNI:0000 0004 7669 9786)
20 PSL University, Mines ParisTech, Inserm, U900, Institut Curie, Paris, France (GRID:grid.58140.38) (ISNI:0000 0001 2097 6957)
21 Beckman Research Institute of City of Hope, Department of Population Sciences, Duarte, USA (GRID:grid.410425.6) (ISNI:0000 0004 0421 8357)
22 University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
23 University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
24 University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
25 University of Newcastle, School of Biomedical Sciences and Pharmacy, Callaghan, Australia (GRID:grid.266842.c) (ISNI:0000 0000 8831 109X); The University of Newcastle and Hunter Medical Research Institute, Discipline of Medical Genetics, Newcastle, Australia (GRID:grid.266842.c) (ISNI:0000 0000 8831 109X); Division of Molecular Medicine, Pathology North, Newcastle, Australia (GRID:grid.266842.c)
26 University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Melbourne, Melbourne, Department of Clinical Pathology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Cancer Genomics Program, Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
27 University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Parkville Familial Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434)
28 Peter MacCallum Cancer Centre, Cancer Genetics Laboratory, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); University of Melbourne, Melbourne, Department of Clinical Pathology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)